Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

492.38 -6.79 (-1.36%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

72 73 Next >

2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher ↗

January 24, 2025

Via The Motley Fool

MaxCyte: Building the Future of Cell and Gene Therapy Innovation

January 23, 2025

MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.

Via MarketBeat

Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever ↗

January 21, 2025

Via The Motley Fool

8 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2025

Via Benzinga

3 Unstoppable Stocks to Buy in 2025 ↗

January 18, 2025

Via The Motley Fool

How Is The Market Feeling About Vertex Pharmaceuticals? ↗

January 15, 2025

Via Benzinga

Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals ↗

January 10, 2025

Via Benzinga

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today ↗

January 07, 2025

Via Benzinga

HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws' ↗

January 16, 2025

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease.

Via Benzinga

Vertex's Pain Drug: Big Pharma's Next Major Success?

January 16, 2025

Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.

Via MarketBeat

Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30? ↗

January 16, 2025

Via The Motley Fool

Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today ↗

January 14, 2025

Via Benzinga

Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials ↗

January 14, 2025

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and strengthens its global drug pipeline.

Via Benzinga

Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts ↗

January 14, 2025

Via The Motley Fool

My 3 Highest-Conviction Growth Stocks to Buy in 2025 ↗

January 13, 2025

Via The Motley Fool

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

January 12, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure ↗

January 10, 2025

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI start-up.

Via Benzinga

Topics Artificial Intelligence

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

January 10, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

January 10, 2025

From Zai Lab Limited

Via Business Wire

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Vertex Grapples With Bearish Chart As Death Cross Emerges ↗

January 07, 2025

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Via Benzinga

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

January 07, 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

Via MarketBeat

Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip ↗

December 28, 2024

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 26, 2024

Via Benzinga

Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip ↗

December 26, 2024

Via The Motley Fool

Top Stock Reports For T-Mobile, Toyota Motor & Vertex Pharmaceuticals ↗

December 24, 2024

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc., Toyota Motor Corp., and Vertex Pharmaceuticals Inc., as well as two micro-cap stocks BK...

Via Talk Markets

Topics Stocks / Equities

3 No-Brainer Stocks to Buy on the Latest Sell-Off ↗

December 24, 2024

Via The Motley Fool

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13

December 23, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst ↗

December 23, 2024

Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 such patients.

Via Benzinga

Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday ↗

December 23, 2024

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.